Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study

Obołończyk, Łukasz; Siekierska-Hellmann, Małgorzata; Wiśniewski, Piotr; Lewczuk, Anna; Berendt-Obołończyk, Monika; Lakomy, Anna; Z, Michalska; Radowska, D; Moszkowska, Grażyna; Bianek-Bodzak, Agnieszka; Sworczak, Krzysztof

doi:10.5604/01.3001.0010.4782

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preexisting abnormalities of thyroid organs are also thought to be predictive factors for IIT in hepatitis C patients. Both pretreatment abnormalities in serum TSH levels and the presence of anti-TPO antibodies at baseline are known to be risk factors for IIT ( 6 , 10 , 15 ). Therefore, prescreening for serum TSH and the presence of anti-thyroid antibodies (anti-TPO antibody and anti-Tg antibody) are recommended in the guidance for interferon treatment of hepatitis C patients ( 6 ).…”

Section: Discussionmentioning

confidence: 99%

Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera

Kirito

2024

Intern. Med.

View full text Add to dashboard Cite

Interferon is an emerging treatment option for myeloproliferative neoplasms (MPNs), especially for polycythemia vera (PV). Previous studies of interferon used therapeutically for hepatitis C have demonstrated that one of the most important adverse events associated with interferon treatment is thyroid dysfunction, and a management strategy for thyroid dysfunction has been established. However, whether or not the recommendation is also suitable for MPN settings is unclear. In this study, one PV patient developed silent thyroiditis during a phase 2 study of ropeginterferon alpha 2b. This case suggests that thyroid dysfunction is an important clinical issue to consider in interferon treatment for PV.

show abstract

Section: Discussionmentioning

confidence: 99%

Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera

Kirito

2024

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…10,11 Nevertheless these medications result in many adverse effects in the HCV positive people, such as flu-like features, bone marrow effects, symptoms pertaining to CNS and many endocrine disorders. 12 Reported prevalence of thyroid diseases in hepatitis C virus positive population is more than in the normal people. 13 Thyroid disorders are suggested because of drugs such as Interferon alpha.…”

Section: Discussionmentioning

confidence: 99%

Thyroid Dysfunction During Combined Pegylated Interferon Alpha and Ribavirin Therapy in Patients of Chronic Hepatitis C-Virus Infection

Mumtaz¹,

Uttra

Ali

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To determine frequency of thyroid dysfunction among patients of chronic hepatitis C receiving combined pegylated interferon alpha and ribavirin therapy. Study Design: Cross sectional study. Place and Duration of Study: Department of Medicine, Military Hospital Rawalpindi, from Jan to Jul 2017. Methodology: One hundred and twenty patients, aged 18–60 years from both genders, with established hepatitis C were included; while the patients with decompensated liver disease, previous antiviral treatment, pre-existing thyroid, autoimmune or severe cardiopulmonary disease and on immuno-suppressants or steroids were excluded. After formal informed consent, they were prescribed 24 weeks pegylated interferon alpha-2 (3 million units subcutaneously thrice weekly) and oral ribavirin (1000–1200 mg daily) therapy. After 12 weeks, serum thyroid stimulating hormone, free thyroxine and triiodothyronine levels were determined by chemiluminescence technique. Results: Out of 120 patients, 100 (83.33%) were males and 20 (16.67%) were females with male to female ratio of 5:1. Mean thyroid stimulating hormone levels at baseline and 12 weeks were 2.86 ± 1.03uiu/ml and 2.16 ± 0.79 uiu/ml respectively. Mean triiodothyronine levels at baseline and 12 weeks were 3.27 ± 1.31pg/ml and 2.69 ± 1.01 pg/ml respectively. Mean thyroxine levels at baseline and 12 weeks were 1.26 ± 0.38 pg/ml and 1.07 ± 0.53 pg/ml respectively. Frequency of thyroid dysfunction was found in 40 (33.33%) patients. Conclusion: Frequency of thyroid dysfunction among hepatitis C patients receiving combined pegylated interferon alpha and ribavirin therapy is quite high.

show abstract

“…The contribution of these problems in the pathophysiology of HT is not fully elucidated, but studies on sibling patients, as well as on monozygotic and dizygotic twins, support a relevant genetic influence on the development of the disease [26]. Environmental factors include: iodine consumption [27], the use of certain drugs, such as α-interferon [28], lithium [29] or immune checkpoint blocking molecules [30] and vitamin D deficiency [32]. A role of Yersinia enterocolitica and Helicobacter pylori infections have been hypothesized in the pathogenesis of thyroid autoimmunity, but only HCV infection, so far, has been associated with an increased risk for the development of Hashimoto's thyroiditis [32].…”

Section: Autoimmune Disorders Of the Thyroid Glandmentioning

confidence: 99%

Do Intestinal Microbiota and Thyroid Travel in Tandem?

Merra¹,

Capacci²,

Lorenzo³

et al. 2022

MPNFS

View full text Add to dashboard Cite

show abstract

Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study

Abstract: Thyroid disorders are common during IFN-α therapy. Previous epidemiological data seem to be underestimated. Important risk factors for IITD development are: female sex, elevated serum TSH concentration (≥2.5 μU/mL), positive TPO-Ab and increased blood velocity in thyroid arteries.

Cited by 6 publications

References 0 publications

Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera

Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera

Thyroid Dysfunction During Combined Pegylated Interferon Alpha and Ribavirin Therapy in Patients of Chronic Hepatitis C-Virus Infection

Do Intestinal Microbiota and Thyroid Travel in Tandem?

Contact Info

Product

Resources

About